InvestorsHub Logo
Followers 113
Posts 25553
Boards Moderated 4
Alias Born 02/01/2004

Re: Ubertino post# 13238

Tuesday, 02/02/2016 7:32:46 PM

Tuesday, February 02, 2016 7:32:46 PM

Post# of 40501
hepatitis b virus

INO-1800 SynCon® immunotherapy for hepatitis B virus


Preclinical

Hepatitis B virus
Milestone

Initiated phase I trial 2Q 2015

Description
INO-1800 is a multi-antigen SynCon® DNA immunotherapy targeting hepatitis B virus clades A & C surface antigens & HBV core antigens.

Development Status
In 2013, Inovio entered into an exclusive worldwide collaboration with Roche to develop and commercialize Inovio’s hepatitis B multi-antigen DNA immunotherapy. The initiation of a phase I trial began in 2Q 2015 to test the safety, tolerability, and immunogenicity of INO-1800 alone or in combination with INO-9112, Inovio’s IL-12-based immune activator.

http://www.inovio.com/products/infectious-disease-vaccines/hepatitis/hbv/

Roche video:

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News